YEAST is a renowned peer-reviewed journal published by WILEY, dedicated to advancing the understanding of yeast biology and its applications in various scientific fields. Since its inception in 1985, YEAST has significantly contributed to the disciplines of microbiology, biotechnology, biochemistry, and genetics, achieving respectable rankings within its categories, including Q2 status in Applied Microbiology and Biotechnology and Q2 in Biotechnology as of 2023. With an emphasis on high-quality research, it explores diverse aspects of yeast organisms, from their cellular mechanisms to biotechnological applications. Although it does not currently offer an open-access option, the journal provides valuable insights and findings that are applicable to both academia and industry, making it an essential resource for researchers, professionals, and students interested in the functional and applied dimensions of yeast. With its editorial rigor and commitment to quality, YEAST continues to be a vital platform for disseminating innovative research that shapes future biotechnological advancements.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE is a leading peer-reviewed publication dedicated to advancing the frontiers of experimental medicine and biomedical research. Published by TOHOKU UNIV MEDICAL PRESS in Japan, this journal has been a vital source of knowledge for over a century, with its historical span ranging from 1920 to 2024. As a Q2 journal in Biochemistry, Genetics and Molecular Biology and Q3 in Medicine, it boasts an impressive Scopus ranking of 144 out of 636 in General Medicine, thereby signifying its strong influence in the field. The journal aims to disseminate critical findings and innovative research methodologies, fostering a collaborative environment among researchers, clinicians, and students. Despite its traditional publishing model, the journal remains committed to contributing significantly to the global scientific community, ensuring that groundbreaking discoveries and experimental techniques are shared with a wide audience, ultimately enhancing healthcare and therapeutic strategies.

Biomedical Research and Therapy is a pioneering journal published by BIOMEDPRESS, dedicated to the field of biomedical sciences. With its ISSN 2198-4093, this journal aims to disseminate high-quality research and innovative therapies that advance knowledge in biomedical research. Although it operates on a non-open access model, it provides crucial insights into various topics such as drug discovery, disease mechanisms, regenerative medicine, and clinical applications. The journal's rigorous peer-review process ensures the publication of critical findings and methodologies, making it a vital resource for researchers, practitioners, and students interested in the constantly evolving landscape of biomedical research. With converged years from 2020 to 2024 and an emerging reputation in its field, Biomedical Research and Therapy is positioned to contribute significantly to the global scientific community, enriching the discourse around therapeutic advancements and biomedical innovations.

Cell Communication and Signaling is a premier peer-reviewed journal published by BMC that has made significant contributions to the fields of biochemistry, cell biology, and molecular biology since its establishment in 2003. As an open access journal, it offers unrestricted access to high-quality research, fostering collaboration and innovation among scientists around the globe. The journal is distinguished by its Q1 ranking in all three relevant categories for 2023, underscoring its critical role in advancing the understanding of cellular communication mechanisms and signaling pathways. Positioned within the United Kingdom, Cell Communication and Signaling has been an invaluable resource for researchers, professionals, and students alike, ensuring that the latest findings are accessible to a diverse range of audiences. With an impressive Scopus ranking—placing it in the top percentiles within its subject areas—this journal continues to set the standard for excellence in the pursuit of understanding complex cellular interactions.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

BioMedicine-Taiwan, published by DIGITAL COMMONS BEPRESS, stands as a prominent open-access journal that has been disseminating vital research since 2014. With an ISSN of 2211-8020 and E-ISSN 2211-8039, this journal covers a wide array of disciplines within the biomedical field, reaching researchers and professionals keen on exploring cutting-edge advancements and innovative approaches in biochemistry, genetics, and general medicine. Notably categorized as Q2 in Biochemistry, Genetics and Molecular Biology and Q3 in Medicine for 2023, BioMedicine-Taiwan ranks well in its respective fields, reflecting its commitment to enhancing scholarly communication and knowledge dissemination. Situated in Taiwan, its impact is further highlighted by its Scopus rankings—placing it in the 70th percentile for general medicine and 47th percentile for general biochemistry and molecular biology, showcasing its significance in ongoing biomedical discourse. Researchers, students, and professionals are invited to engage with this invaluable resource to explore the latest findings and developments that shape the future of healthcare and biological sciences.

FOLIA BIOLOGICA, published by Charles University Prague, First Faculty of Medicine, is an esteemed academic journal that has been contributing to the fields of Biochemistry, Cell Biology, Developmental Biology, Genetics, Immunology, and Molecular Biology since its inception in 1961. With an ISSN of 0015-5500, this journal serves as a vital platform for researchers and professionals to disseminate their findings and advance knowledge within these disciplines. Despite its current Category Quartiles ranking in the lower tiers (Q3 and Q4), FOLIA BIOLOGICA continues to provide valued insights and foster scholarly dialogue, particularly in its paralleled fields. The journal is headquartered in Prague, Czech Republic, and operates without Open Access options, which emphasizes its focus on curated, peer-reviewed content essential for academicians and students. By bridging theoretical and practical knowledge, FOLIA BIOLOGICA remains committed to enriching the scientific community and serving as a cornerstone for future research innovations.

EXCLI Journal is an esteemed open access scientific publication dedicated to the fields of Animal Science and Zoology, Drug Discovery, Molecular Medicine, and Pharmacology. Established in 2002 and published by the EXCLI JOURNAL MANAGING OFFICE, this journal has quickly ascended in the academic community, securing a Q1 classification in significant categories like Animal Science and Drug Discovery in the 2023 rankings. With an impressive Scopus Rank of #13 out of 490 in its primary field, the journal maintains high standards for quality research and innovation. The EXCLI Journal is committed to disseminating progressive findings with global relevance, providing a platform for researchers, professionals, and students to engage with cutting-edge studies. With a compelling aim to foster knowledge exchange and collaboration among scientists worldwide, this journal signifies a critical resource for those invested in advancing our understanding of animal science and pharmaceutical research.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.